International Isotopes Stock Price, News & Analysis

International Isotopes Inc. reported a significant 16% increase in revenue for the fiscal year 2022, totaling $11.2 million, the highest in the company's history. The net income rose to approximately $300,000, a turnaround from a net loss of about $900,000 in 2021. The radiochemical segment was pivotal, achieving a 41% sales increase and accounting for 54% of total sales. Additionally, the company realized a net gain of $1.8 million from the sale of unused assets. Despite rising costs leading to a decrease in gross profit margin to 56%, the year-end cash balance improved to approximately $2.4 million.

International Isotopes Inc. (OTCQB: INIS) reported a 9% revenue increase for the first nine months of 2022, totaling $8,031,522, compared to $7,369,922 in 2021. The company achieved a net profit of $414,328 year-to-date. However, the cost of sales rose by approximately 15%, and operating expenses increased by 19% primarily due to heightened R&D costs. Despite these challenges, the cash balance remains strong at $3,000,000. Management anticipates continued growth in various segments, including radiochemical products.

International Isotopes Inc. (OTCQB: INIS) reported a 10% increase in revenue, totaling $5,242,249 for the six months ending June 30, 2022, compared to $4,752,408 in 2021. The net income for the same period was $982,997, a significant rebound from a loss of $782,539 in 2021, largely due to a $1.8 million gain from asset sales. However, revenue for the second quarter alone decreased by 12% to $2,434,808, driven by diminished cobalt sales. Revenue from radiochemical products surged by 59% for the six-month period.